Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIVOT: Induction Chemoimmunotherapy in Unresectable Locally Advanced NSCLC
NCT07632365Phase 2Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Oct 2022
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoints: Incidence of Grade 3 or Higher Treatment-Related Adverse Events and Progression-Free Survival at 36 months. Started Oct 2022; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07632365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07632365.